Picture loading failed.

Anti-MAPT therapeutic antibody (Pre-made Tilavonemab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tilavonemab (formerly C2N 8E12) is a humanised recombinant anti-human tau monoclonal antibody, being developed by AbbVie and C2N Diagnostics for the treatment of various neurological disorders including Alzheimer's disease.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-572-1mg 1mg 3090
GMP-Bios-ab-572-10mg 10mg 21890
GMP-Bios-ab-572-100mg 100mg 148000
GMP-Bios-ab-572-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-MAPT therapeutic antibody (Pre-made Tilavonemab biosimilar,Whole mAb)
INN Name Tilavonemab
TargetMAPT
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesAbbVie;C2N Diagnostics
Conditions Approvedna
Conditions ActiveAlzheimer's disease;Progressive supranuclear palsy
Conditions Discontinuedna
Development Techna